Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > April 27, 2020
Daily News
April 27, 2020
- Blurred Outlook for Off-Year Drug Re-Pricing, Will Japan Go Ahead with April 2021 Plan?
April 27, 2020
- Novartis Japan Scraps Sales Offices to Boost Efficiency of Rep Activities
April 27, 2020
- Japan Starts Assessing Performance of Antibody Test Kits: Minister
April 27, 2020
- Drug Makers Should Join in “Concerted National Effort” to Propel Regulatory Harmonization in Asia: Ex-PMDA Chair
April 27, 2020
- AbbVie’s Rinvoq, MSD’s Noxafil Tablets Now Available
April 27, 2020
- IFPW Postpones Tokyo General Meeting to October 2021
April 27, 2020
- Takeda Inks US$670 Million Divestment Deal for Europe OTC Biz
April 27, 2020
- Ohara Launches New Firm on Former Teva Takeda Site in Shiga Prefecture
April 27, 2020
- Sumitomo Dainippon, NIBIOHN Team Up on Universal Influenza Vaccine
April 27, 2020
- Fujifilm Commences Japan PI Study of Radioisotope Conjugate Antibody FF-21101
April 27, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…